The ISDA Regulatory Margin Self-Disclosure Letter – India Supplement published on July 12, 2024 is… Read more ISDA Regulatory Margin Self-Disclosure Letter – India
Filter by Category
ISDA letter to BCBS/IOSCO relating to issues concerning timing requirements for margin delivery.
Proposed rules by EU and the US regulators require, with some exceptions, the collection of... Read more ISDA letter to BCBS/IOSCO relating to issues concerning timing requirements for margin delivery.
Documents (1) for ISDA letter to BCBS/IOSCO relating to issues concerning timing requirements for margin delivery.
ISDA letter responding to the CFTC’s proposed cross-border rules for margin
ISDA provides comments to the CFTC regarding the recently proposed rulemaking relating to the cross-border... Read more ISDA letter responding to the CFTC’s proposed cross-border rules for margin
Documents (1) for ISDA letter responding to the CFTC’s proposed cross-border rules for margin
ISDA letter to PRs, CFTC and the SEC regarding certain aspects of the margin requirements for uncleared swaps.
ISDA letter addressing various issues related to margin requirements for uncleared swaps, which follows discussions... Read more ISDA letter to PRs, CFTC and the SEC regarding certain aspects of the margin requirements for uncleared swaps.
Documents (1) for ISDA letter to PRs, CFTC and the SEC regarding certain aspects of the margin requirements for uncleared swaps.
ISDA letter to the ESAs on the Second Consultation Paper regarding draft regulatory technical standards on risk-mitigation techniques for OTC-derivative contracts not cleared by a CCP
ISDA responds to the Second Consultation Paper on the draft regulatory technical standards on risk-mitigation... Read more ISDA letter to the ESAs on the Second Consultation Paper regarding draft regulatory technical standards on risk-mitigation techniques for OTC-derivative contracts not cleared by a CCP
Documents (1) for ISDA letter to the ESAs on the Second Consultation Paper regarding draft regulatory technical standards on risk-mitigation techniques for OTC-derivative contracts not cleared by a CCP
ISDA letter to global regulators on the use of a broad product set for purposes of margin calculation
The scope of products subject to the proposed margin requirements is not consistent across the... Read more ISDA letter to global regulators on the use of a broad product set for purposes of margin calculation
Documents (1) for ISDA letter to global regulators on the use of a broad product set for purposes of margin calculation
ISDA Minimum Considerations for Uncleared Margin-Future State Workflow (MCD 2.0)
The document puts forth considerations for the end to end process changes needed from an... Read more ISDA Minimum Considerations for Uncleared Margin-Future State Workflow (MCD 2.0)
Documents (1) for ISDA Minimum Considerations for Uncleared Margin-Future State Workflow (MCD 2.0)
ISDA Minimum Standards Document for the Future State Margin Workflow (MSD V1.0)
The purpose of the “MSD for the Future State Margin Workflow” is to define recommended... Read more ISDA Minimum Standards Document for the Future State Margin Workflow (MSD V1.0)
Documents (1) for ISDA Minimum Standards Document for the Future State Margin Workflow (MSD V1.0)
ISDA WGMR Implementation Initiative
Creating a New CSA under New York Law and English Law: ISDA and IHS Markit Tutorial... Read more ISDA WGMR Implementation Initiative
Documents (0) for ISDA WGMR Implementation Initiative
ISDA 2016 Variation Margin Protocol
To adhere to the Protocol and for FAQs and other information regarding the Protocol, please... Read more ISDA 2016 Variation Margin Protocol
Documents (0) for ISDA 2016 Variation Margin Protocol
Consultation Paper regarding draft regulatory technical standards on risk-mitigation techniques for OTC-derivative contracts not cleared by a CCP
ISDA and SIFMA respond to the Consultation Paper on the Draft regulatory technical standards (the... Read more Consultation Paper regarding draft regulatory technical standards on risk-mitigation techniques for OTC-derivative contracts not cleared by a CCP